Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19698919 | 0.75 | ADORA2A (0.44) | ADORA2AADORA1ADORA2BRAB9ASMN1; SMN2 | |
| SCHEMBL24539874 | 0.72 | ADORA2A (0.45) | ADORA2AADORA1ADORA2BRAB9ASMN1; SMN2 | |
| SCHEMBL30277827 | 0.72 | ADORA2A (0.50) | ADORA2AADORA1ADORA2BRAB9ASMN1; SMN2 | |
| SCHEMBL24170311 | 0.72 | ADORA2A (0.50) | ADORA2AADORA1ADORA2BRAB9ASMN1; SMN2 | |
| SCHEMBL5065955 | 0.71 | ADORA2A (0.56) | ADORA2AADORA1ADORA2BAXLMKNK1 | |
| SCHEMBL61008 | 0.71 | ADORA2A (0.49) | ADORA2AADORA1ADORA2BRAB9ASMN1; SMN2 | |
| SCHEMBL29661378 | 0.71 | ADORA2A (0.56) | ADORA2AADORA1ADORA2BAXLMKNK1 | |
| Hydrochloric Acid SCHEMBL30277817 | 0.71 | ADORA2A (0.49) | ADORA2AADORA1ADORA2BRAB9ASMN1; SMN2 | |
| SCHEMBL3278516 | 0.71 | GPR3 (0.53) | ADORA2AADORA1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL20783852 | 0.68 | RAB9A (0.41) | ADORA2AADORA1ADORA2BRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683171-B2 | N,1-Dimethyl-7-phenyl-1H-imidazo[4,5-d]thieno[3,2-b]pyridin-4-amine; treating inflammatory and immune diseases; cancer; I kappa B kinase (IKK) inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-23 | — | — | US | disclosed |
| US-20060178393-A1 | 1H-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178393-A1 | 1H-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | IL4, IL5, IRAK4 | ADORA2A 329/4885ADORA1 122/4885ADORA2B 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.